The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.
first published: Mar 12, 2012 09:59 pm
A collection of the most-viewed Moneycontrol videos.
Iran Rejects US Talks Again, Strait Of Hormuz Tensions Rise As Oil Route Risks Grow
PM Modi Targets Congress After Women Reservation Bill Defeat, Vows To Remove Obstacles | FULL SPEECH
Trump Claims Iran Will Never Shut Hormuz Again, Big Statement Raises Global Questions
AMIT SHAH FULL SPEECH: Amit Shah Addresses Lok Sabha on Reservation, Delimitation & Representation
